Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand [Benzinga]
May 16, 2024
Major deals continue positive trajectory for psychedelics in 2024 [Psychedelic Health]
May 16, 2024
$6M bankrolls Enveric pipeline partnering, depression program [Green Market Report]
May 15, 2024
Psychedelics for Depression: MindBio and Enveric’s Joint Efforts [TDR]
May 15, 2024
Enveric Biosciences to out-license psilocin prodrug to MindBio [Pharmaceutical Technology]
May 15, 2024
Enveric signs deal with MindBio [Green Market Rerport]
May 14, 2024
Advancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics [Microdose]
May 14, 2024
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders [Psychedelic Invest]
May 14, 2024
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate [Benzinga]
May 14, 2024
A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies [Microdose]
May 8, 2024
‹
1
2
3
4
…
11
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
